Deal for Irinotecan Hydrochloride with Yakult Honsha Terminates

For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshio Takahashi, Corporate Officer in Charge, Corporate Communications Department Telephone: +81-3-6225-1126 http://www.daiichisankyo.com/ Deal for Irinotecan Hydrochloride with Yakult Honsha Terminates Tokyo, August 29, 2007 - DAIICHI SANKYO COMPANY, LIMITED has announced today that deal for the anticancer drug irinotecan hydrochloride with Yakult Honsha Co., Ltd. (President: Sumiya Hori) will terminate effective September 17, 2007 as the use patent for the drug expires. After the termination of this deal, the two companies will independently pursue irinotecan hydrochloride businesses. End

The release as fetched from its publisher. daiichisankyo.com ↗